中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Milestones
Pipeline
Ophthalmology
Business Development
Business Development
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Business Development
Business Development
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
News
Press Releases
In The News
Media Room
Feb 15,2022
15
February 2022
AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases
Jan 19,2022
19
January 2022
AffaMed Therapeutics Doses First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA in China in Cataract Surgery Patients
Jan 11,2022
11
January 2022
AffaMed Technologies Announces Successful Completion of First Patient Implantations of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in Boao, Hainan
Jan 03,2022
03
January 2022
AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical to Develop and Commercialize Risuteganib (Luminate®)
as a First-In-Class Treatment for Intermediate Dry AMD Patients in Greater China
Nov 03,2021
03
November 2021
Supplemental New Drug Application for DEXTENZA Approved by FDA for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
<<
<
1
2
3
4
5
6
>
>>
上一页
下一页
